



OPEN LETTER

# Insights from quantitative and mathematical modelling on the proposed 2030 goal for gambiense human African trypanosomiasis (gHAT) [version 1; peer review: 1 approved, 1 approved with reservations]

NTD Modelling Consortium Discussion Group on Gambiense Human African Trypanosomiasis 

**v1** **First published:** 07 Oct 2019, 3:1553 (<https://doi.org/10.12688/gatesopenres.13070.1>)  
**Latest published:** 07 Oct 2019, 3:1553 (<https://doi.org/10.12688/gatesopenres.13070.1>)

## Abstract

Gambiense human African trypanosomiasis (gHAT) is a parasitic, vector-borne neglected tropical disease that has historically affected populations across West and Central Africa and can result in death if untreated. Following from the success of recent intervention programmes against gHAT, the World Health Organization (WHO) has defined a 2030 goal of global elimination of transmission (EOT). The key proposed indicator to measure achievement of the goal is to have zero reported cases. Results of previous mathematical modelling and quantitative analyses are brought together to explore both the implications of the proposed indicator and the feasibility of achieving the WHO goal.

Whilst the indicator of zero case reporting is clear and measurable, it is an imperfect proxy for EOT and could arise either before or after EOT is achieved. Lagging reporting of infection and imperfect diagnostic specificity could result in case reporting after EOT, whereas the converse could be true due to underreporting, lack of coverage, and cryptic human and animal reservoirs. At the village-scale, the WHO recommendation of continuing active screening until there are three years of zero cases yields a high probability of local EOT, but extrapolating this result to larger spatial scales is complex.

Predictive modelling of gHAT has consistently found that EOT by 2030 is unlikely across key endemic regions if current medical-only strategies are not bolstered by improved coverage, reduced time to detection and/or complementary vector control. Unfortunately, projected costs for strategies expected to meet EOT are high in the short term and strategies that are cost-effective in reducing burden are unlikely to result in EOT by 2030. Future modelling work should aim to provide predictions while taking into account uncertainties in stochastic dynamics and infection reservoirs, as well as assessment of multiple spatial scales, reactive strategies, and measurable proxies of EOT.

## Keywords

gambiense human African trypanosomiasis (gHAT), sleeping sickness,

## Open Peer Review

Reviewer Status  

	Invited Reviewers	
	1	2
<b>version 1</b> published 07 Oct 2019	 report	 report

1 **Michael P. Barrett**, University of Glasgow, Glasgow, UK

2 **Mario Recker**, University of Exeter, Penryn, UK

Any reports and responses or comments on the article can be found at the end of the article.

WHO goals, elimination of transmission, NTD Modelling Consortium, prediction



This article is included in the [2030 goals for neglected tropical diseases](#) collection.

**Corresponding author:** NTD Modelling Consortium Discussion Group on Gambiense Human African Trypanosomiasis ([K.S.Rock@warwick.ac.uk](mailto:K.S.Rock@warwick.ac.uk))

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by the Bill and Melinda Gates Foundation [OPP1184344, OPP1177824] through the NTD Modelling Consortium (KSR, MJK, MA, NC, SC) and the HAT Modelling and Economic Predictions for Policy (HAT MEPP) project (KSR, MJK, MA, FT, REC, CH). CND was funded by EPSRC/MRC via the MathSys Centre for Doctoral Training.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 NTD Modelling Consortium Discussion Group on Gambiense Human African Trypanosomiasis. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** NTD Modelling Consortium Discussion Group on Gambiense Human African Trypanosomiasis. **Insights from quantitative and mathematical modelling on the proposed 2030 goal for gambiense human African trypanosomiasis (gHAT) [version 1; peer review: 1 approved, 1 approved with reservations]** Gates Open Research 2019, 3:1553 (<https://doi.org/10.12688/gatesopenres.13070.1>)

**First published:** 07 Oct 2019, 3:1553 (<https://doi.org/10.12688/gatesopenres.13070.1>)

**Disclaimer**

The views expressed in this article are those of the authors. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the World Health Organization. Publication in Gates Open Research does not imply endorsement by the Gates Foundation.

**Background**

Gambiense human African trypanosomiasis (gHAT, sleeping sickness) is an infection caused by the parasite *Trypanosoma brucei gambiense*, spread through blood-meal feeding by tsetse in West and Central Africa. Disease symptoms caused by gHAT generally progress over multiple years. Stage 1 disease is defined as the time before the parasite crosses the blood-brain barrier, with symptoms such as headache and fever, whereas stage 2 involves neurological symptoms and typically death if left untreated. Fortunately, there are a variety of tools available to assist in the control of gHAT and these have been effective at reducing the burden of gHAT from 37,385 cases in 1998 to 953 cases in 2018<sup>1</sup>. The primary intervention against gHAT is large-scale, test-confirm-and-treat strategies with diagnosis and confirmation performed by mobile teams in at-risk villages, followed by hospitalisation for treatment; 56% of detected cases in 2016 were diagnosed in this way<sup>2</sup>. The rest of cases are identified through passive surveillance (self-presentation) in fixed health facilities. There are additional options to reduce transmission by targeting the tsetse vector directly, which has been implemented successfully in several regions, but is currently a non-standard component of intervention strategies in most areas.

Previously, the World Health Organization (WHO) roadmap set a target of elimination as a public health problem (EPHP)

for gHAT by 2020<sup>2</sup>, which has been redefined as (a) having fewer than 2000 globally reported cases and (b) at least a 90% reduction in areas reporting >1 case per 10,000 people over a five-year period (2016–2020) compared to a 2000–2004 baseline (Table 1)<sup>3</sup>. It is complex to determine yet whether the second indicator will be met without a detailed analysis of global data; however, 1419 cases were reported in 2017 and 953 were reported in 2018, suggesting that the first indicator should have been not only met but greatly surpassed. The subsequent WHO goal is global elimination of transmission (EOT) by 2030 (Table 1)<sup>4</sup>. Achievement of EOT for gHAT would not only represent a huge stand-alone accomplishment but would place gHAT amongst the very select group of infections for which, through deliberate intervention, global EOT has already been achieved (smallpox and rinderpest) or may be met by 2030 (e.g. Guinea worm and polio).

Predictive, mechanistic modelling is a data-driven approach to explore the feasibility of reaching the WHO goals, taking into account the known biology of infection but also representing uncertainty in all processes. Recent mathematical modelling by the NTD Modelling Consortium and collaborators - including groups from the Institute for Disease Modeling, the Swiss Tropical and Public Health Institute, University of Warwick and Yale University - has provided quantitative perspectives on the challenges of reaching and the likelihood of achieving both the 2020 and 2030 WHO goals for gHAT. The following sections outline some of the key model findings that are of direct relevance to the 2030 EOT goal.

**Modelling insights from strategies previously conducted**

In the last two decades, the predominant strategy against gHAT was medical only, comprising active screening and passive

**Table 1. Summary of modelling perspectives of the WHO goals for gambiense human African trypanosomiasis (gHAT).**

Current WHO Goal (2020 Goal)	Elimination as a public health problem (EPHP). Indicators: (a) <2000 cases globally; and (b) >90% reduction in areas reporting >1 case/10,000 people in 2016–2020 compared to 2000–2004.
Proposed WHO Goal (2030 Goal)	Elimination of transmission (EOT). Indicators: (a) zero reported cases; (b) 90% reduction in high and moderate risk areas relative to 2020 baseline; and (c) >50% and >95% of at-risk populations <1 hour and <5 hours from a health facility with gHAT diagnostics, respectively.
Is the new target technically feasible under the current disease strategy?	The target is likely to be technically feasible using existing tools but would require a step change in the level of surveillance and the use of additional controls (such as door-to-door screening or vector control) in persistent regions.
If not, what is required to achieve the target?	New rapid diagnostic tests, together with 2030 health facility targets, will help case detection. New drugs should improve compliance and ease of treatment. Novel targeted surveillance approaches may be needed close to elimination.
Are current tools able to reliably measure the target?	Yes - existing diagnostics are likely sufficient. However, the indicator of zero reported cases does not imply that the goal of EOT has been reached.
What are the biggest unknowns?	Prevalence of infection in regions that have never had active surveillance. The role of asymptomatic infections and animal reservoirs as elimination is approached.
What are the biggest risks?	Lack of participation in surveillance at a range of scales. Inability to screen and treat due to conflict. Reduction in controls, particularly passive surveillance, once zero cases are reported locally.

surveillance followed by treatment. Current medical-based gHAT control strategies are working well in reducing incidence<sup>2</sup> and modelling indicates they are also reducing underlying transmission<sup>5,6</sup>. Shortening time to detection and treatment of cases further reduces morbidity and subsequent onward transmission<sup>7</sup>. Modelling indicates that, in Uganda and South Sudan, passive surveillance reduced transmission by 30-50% during the 1990s and 2000s; strengthening these systems in gHAT endemic regions could therefore have great potential<sup>8</sup>. Staged gHAT case data (differentiating between stage 1 and stage 2 cases) can provide substantial information on the effectiveness of, and changes in, the passive surveillance system; for example, improvement in time to detection in former Bandundu province in the Democratic Republic of the Congo (DRC) is reflected in a greater proportion of stage 1 cases<sup>9</sup>.

Despite these successes, controls can be disrupted by conflict or other events; notably, the Ebola epidemic in West Africa resulted in temporary cessation of medical activities<sup>10</sup>. Furthermore, in higher endemicity settings or regions with little screening, the current medical-only interventions are predicted to be insufficient for achieving EOT by 2030 (e.g. in several health zones in Bandundu, DRC, EOT is predicted to be realised after 2050)<sup>11-13</sup>. In these settings - assuming scale up of vector control (VC) is feasible and the substantial (>80%) reduction in tsetse density<sup>14,15</sup> can be reproduced widely - supplementing medical interventions with VC is predicted to be cost-effective at relatively low willingness-to-pay (WTP) thresholds in high-risk areas<sup>13</sup>, and to lead to EOT in much shorter timescales (1-6 years instead of >30 years in some settings)<sup>11,12</sup>.

### What are the practical implications of the elimination of transmission goal?

The WHO 2030 goal for gHAT is EOT globally, with the key proposed indicator of achieving zero reported cases (Table 1). Other proposed indicators relate to sustaining coverage of passive surveillance.


### Measuring the target

In the long term, reaching EOT will lead to zero detected cases; however, the two objectives are not equivalent - it is possible either that zero case detections could occur without EOT or, conversely, that gHAT detections could be observed even after EOT.

**EOT before zero reporting.** Achieving EOT may not immediately lead to zero detected cases as there is often a long period between infection and detection (several years is typical<sup>16</sup>, although in extreme cases this could be decades<sup>17</sup>). As EOT is approached, the choice of confirmatory diagnostics becomes increasingly important as imperfect test specificity, even current algorithms with ~99.9% specificity, can lead to false positive cases. As we approach the 2030 goal, more rigorous methodologies (e.g. the laboratory-based trypanolysis test with 100% specificity<sup>18</sup>) should help to circumnavigate this problem.

**Zero reporting but not EOT.** Achieving zero detected cases does not mean that there is EOT for numerous reasons. The first possibility is that screening does not identify all remaining infections at peri-elimination. Only some of the population at risk is regularly screened; modelling<sup>5,6,9</sup> suggests that some high-risk individuals (~20% of the population) may not attend active screenings and data show that not all settlements in high-risk areas are screened annually (around 50% of villages in a high-endemicity region of DRC were screened in any given year<sup>4,19</sup>). Coverage may improve with mini mobile teams (screening otherwise inaccessible villages) or door-to-door screening (likely increasing the number of high-risk people participating), but pockets of infection could still be missed. Furthermore, large areas of DRC (Figure 1), South Sudan and Central African Republic with potential transmission are not regularly screened due to regional conflicts. Secondly, even where there is a functional health system, there is a high probability of underreporting; models for Bandundu, DRC, suggest that only around 20% of gHAT cases that escape active detection are identified by passive detection (Model W in Rock *et al.*<sup>9</sup>), corresponding to ~63% of all infections being unreported.

Models can be used in order to explore the predictive power of one or more years of zero detected cases in estimating the



**Figure 1. Geographic availability of gambiense human African trypanosomiasis (gHAT) data across the Democratic Republic of the Congo.** Colours represent numbers of reported cases in health zones from the last five years of data set. Health zones that never (2000–2016) report cases or active screening are coloured grey, whilst zones with <5% mean active screening coverage (during 2012–2016) are shown with black dots. This figure has been adapted from data presented in Franco *et al.*<sup>1</sup> under a CC-BY 4.0 license and with permission from Dr Erick Mwamba Miaka, director of the National HAT Control Programme (PNLTHA) of the Democratic Republic of the Congo.

likelihood of EOT. A stochastic village-level model (replaying active screening from 2000-16 for 559 settlements in Yasa Bonga & Mosango, Bandundu, DRC) focussed on detecting zero cases under active screening. This model strongly indicates that three or more consecutive rounds of finding zero cases is sufficient to reach >90% positive predictive value (PPV) of local EOT across typical village sizes and where screenings that achieve <10% coverage were ignored (Figure 2)<sup>19</sup>. There is higher certainty of EOT in smaller settlements and only using active screenings with >50% coverage as a measure could reduce the number of screening rounds needed to have high confidence. Current WHO guidelines recommend conducting three consecutive years of active screening with zero detections in a village before stopping<sup>7</sup>, therefore providing high confidence of local EOT prior to cessation. Modelling suggests that factoring screening coverage and population size into future guidelines could further improve certainty that EOT is met before stopping and could reduce the number of zero detections required for smaller settlements if coverage is sufficient. Scaling these insights from the village to larger spatial scales is confounded by spatial correlations and reinvasion, suggesting an intelligent and reactive surveillance methodology is required.

Finally, there is potential for circulation of infection in animal reservoirs or persistence in asymptomatic individuals, which could lead to resurgence even after zero human reporting<sup>20</sup>.

#### Technical feasibility

Models predict that for some regions (e.g. Equateur, DRC) continuation of the current medical-only strategy could achieve local EOT by 2030<sup>11</sup>; however, in other regions (particularly some of Bandundu, DRC) this strategy may need to be supplemented with additional or improved interventions, even in

areas likely to meet EPHP by 2020<sup>12</sup>. Local EOT may be unsustainable without continued control due to the risk of reinvasion from other infected areas.


Multiple modelling approaches have shown that improvements to passive surveillance, targeting active screening to include high-risk groups, and VC could all result in reduced transmission and lead to EOT by 2030 with higher probability than the current medical-only strategy<sup>9,21</sup>. Whilst it may not be necessary to implement VC across all settings, modelling consistently finds that VC averts infections fastest amongst the considered strategies. Modelling also suggests that the use of other new technologies (i.e. new oral drugs and RDTs) could lead to EOT but with lower probability and slower timelines than VC<sup>13</sup>.

#### Operational feasibility

Modelling results are generally based on assumptions that the health system retains similar or better functionality over the next 10 years. Political instability, conflict, or a reduced priority for tackling the reduced number of future cases could all lead to less control being applied in the future. Models are therefore making assumptions that screening and other controls follow recent trends.

#### Ability to sustain achievement of the goal

Stopping large-scale control activities against gHAT too soon could be problematic for EOT. Modelling was used to explore potential resurgence following attainment of EPHP in Guinea<sup>22</sup>, concluding that the presence of animal reservoirs would likely lead to resurgence following cessation of screening and vector control, but resurgence was unlikely if transmission was anthroponotic. Indeed, interruption of medical interventions



**Figure 2. Probability of elimination of transmission (EOT) at the village-level based on case reporting.** The positive predictive value (PPV) of zero case detections to assess whether local EOT has occurred is the probability of zero human infection given consecutive active screenings with no cases found and no passive reporting in between (for >2 screenings). Model parameterization is for Yasa Bonga and Mosango health zones in the Democratic Republic of the Congo. The left figure uses all active screenings with >10% coverage, while the right figure is restricted to screenings of >50% coverage. The yellow region indicates >90% confidence that EOT has been met locally. This figure has been reproduced with permission from Davis *et al.*<sup>19</sup>.

in Guinea during the Ebola outbreak has shown that early cessation of activities in low prevalence settings can still lead to resurgence over three years<sup>10</sup>. In contrast, regions that maintained VC but stopped medical intervention observed a decrease in prevalence during the same time period<sup>23</sup>.

Even if an area has reached local EOT, there is a concern that cessation of activities could be risky if nearby places have on-going transmission. Modelling reinvasion of HAT in villages in DRC that have achieved local EOT suggests short-term reinvasion is likely (>70%) from a single infected person, but less likely to cause persistent infection for ~15 years (<20%)<sup>19</sup>.

### Considerations of costs and allocative efficiency

The burden of NTDs falls in resource-poor settings, and it is of utmost importance to efficiently use the resources available. A cost-effectiveness analysis for gHAT across settings of different transmission intensities has found that VC combined with other new technologies (diagnostics and drugs) is likely to be highly cost-effective in high-transmission settings (i.e. cost-effective for WTP thresholds >\$386/disability-adjusted life year [DALY] averted). In moderate-transmission settings this strategy is only likely to be cost-effective for high WTP thresholds (>\$1509/DALY averted), with medical-only strategies using new technologies likely to be preferable for lower WTP thresholds<sup>13</sup>. Unfortunately, cost-effectiveness in this traditional net-benefits framework does not always align with the goal of EOT by 2030, as strategies that are cost-effective (in terms of DALYs versus costs) may not be sufficient to meet the EOT goal. For example, in Sutherland *et al.*<sup>13</sup>, VC strategies were generally required to have high predicted probability of EOT by 2030, despite having low probabilities of being cost-effective in moderate- or low-transmission settings.

An analysis on the affordability of gHAT intervention and patient financial impact estimated that the total costs of a global control or elimination programme would be substantial (depending on the programme, between US\$410.9 million and US\$1.2 billion, compared to US\$630.6 million for control activities in 2013-2020)<sup>24</sup>. Alleviation of impoverishment and catastrophic health expenditures for households due to gHAT infection can only be achieved through elimination, rather than control, programmes.

### Risks and unknowns faced by gHAT elimination programmes

A more complete review of key factors that may impact the EOT goal is given by Büscher *et al.*<sup>20</sup>. Here, insights arising from modelling-based studies are discussed.

### Systematic non-participation in screening

Several modelling studies suggest that there is systematic non-participation in active screening, with high-risk individuals less likely to participate; the models without this heterogeneity were unable to match the observed longitudinal patterns of cases across different regions<sup>5,6</sup>. More detailed data on age and gender of screening participants and gHAT cases could help better elucidate key groups in the population most responsible for transmission.

### Animal reservoirs

Although prevalence of gHAT infection in animals is nonzero, estimates are uncertain and the role of infected animals in onward transmission is unclear<sup>20</sup>. One modelling study using point prevalence data from animals in Cameroon suggested that animals constitute a possible transmission reservoir, implying that control targeting only human cases would be unable to eliminate gHAT due to persistence in animals<sup>25</sup>, whereas modelling using longitudinal human data (Guinea, DRC, Chad) suggest that there is comparable statistical support for models with and without an animal reservoir<sup>5,6,22</sup>. However, animals are unlikely to be able to sustain transmission on their own in Chad<sup>5</sup>.

Modelling suggests that VC, including spraying livestock, would reduce any possible transmission from animals, although pockets of sustained transmission could occur away from human activities<sup>26</sup>.

### Asymptomatic reservoirs

Asymptomatic infections in humans have been considered in a few transmission models. In some<sup>9,21</sup>, the role of these infections in maintaining transmission or causing resurgence was unclear, although one modelling study using data from Guinea found both asymptomatic and clinical human infections were necessary for gHAT to persist (assuming no animal reservoir) and concluded that passive surveillance alone was not sufficient for gHAT monitoring in the approach to elimination<sup>27</sup>.

### Movement

So far, little attention has been paid to the movement of people in the modelling literature on gHAT; however, this may be important in areas that recently achieved disease-free status. Particular regions of concern would include formally endemic areas with both high influxes of refugees/internally displaced people and limited surveillance.

### Immediate priorities

Table 2 highlights a list of priority questions for modellers that are of relevance for the 2030 EOT goal for gHAT arising from discussions between modellers and WHO.

**Table 2. Immediate priorities for modelling for gambiense human African trypanosomiasis (gHAT).**

Priority issue / question identified by WHO during this meeting	How can modelling address this?
<b>Probability of interrupted transmission:</b> Can existing mathematical models be used to define the probability of interruption of gHAT transmission in regions where no cases have been detected?	Using historic data, and assumptions on current passive surveillance, models can be generated that capture the observed dynamics at regional foci and calculate the probability (PPV) of interrupted transmission given that no cases have been reported for different periods of time.
<b>Reactive screening:</b> How does a reactive screening strategy compare to active screening and passive detection, or passive detection alone in terms of: - reduction of transmission (amount and timescales)? - case reporting?	Modelers can develop/refine modelling of current active and passive strategies to extend to simulate a reactive screening strategy. - The spatial scale considered will impact results. - Reactive strategies can and should be included in cost predictions and cost-effectiveness analyses
<b>Animal reservoir:</b> - What do we know about their role in transmitting disease? - How could an animal reservoir affect the 2030 target?	Some modelling has already explored possible animal reservoirs. Modelers can continue to explore: - Whether there are signals of animal reservoirs by assessing human case data alone - If there is any support for these models, to assess the relative contribution of animals to transmission, and what impact this could have on timescales to achieve EOT - To include animals in a village-scale model framework (to assess PPV of zero case detections in active screening on EOT) - To make estimates more robust by fitting to human and animal data (if available) - To assess implications of animal reservoirs in decision analyses between interventions
<b>Asymptomatics:</b> - Can we estimate potential number of asymptomatics? E.g. for one detected case, how many go undetected? - How likely are asymptomatics to infect others? - What do we know about their role in (maintaining) transmission?	- Existing modelling frameworks can be adapted to include potential asymptomatics (including self-cure or skin infections) - Sensitivity analysis and/or matching to data (if available) could estimate possible numbers of asymptomatics, relative contribution to transmission, infection timescales, and relative infectivity. Lack of data may lead to large confidence intervals - Modelers can evaluate the effectiveness of different strategy types in models with and without asymptomatic people - e.g. would we select the same intervention strategy if asymptomatics play a substantial role in transmission?
<b>Spatial prediction:</b> Support defining areas that should be screened, where there is potential of transmission. Similarly, can we rule out certain areas?	- A tsetse absence model could be used to assess regions which are unlikely to have gHAT due to unsuitable habitat. - This can be used to explore the joint distribution of the active and passive surveillance data and to look for factors/variables which could predict the underlying variation and probability of reporting. - It may be possible to include a range of factors into these predictions including changing population distribution and land-use.

## Data availability

No data are associated with this article.

## Acknowledgements

*NTD Modelling Consortium discussion group on gambiense human African trypanosomiasis (gHAT):*

Kat S Rock ([k.s.rock@warwick.ac.uk](mailto:k.s.rock@warwick.ac.uk); corresponding author)<sup>1,2</sup>, Ronald E Crump ([r.e.crump@warwick.ac.uk](mailto:r.e.crump@warwick.ac.uk))<sup>1,2</sup>, Christopher Davis ([c.davis.3@warwick.ac.uk](mailto:c.davis.3@warwick.ac.uk))<sup>1,2</sup>, María Soledad Castaño ([soledad.castano@unibas.ch](mailto:soledad.castano@unibas.ch))<sup>3,4</sup>, Marina Antillon ([marina.antillon@swissth.ch](mailto:marina.antillon@swissth.ch))<sup>3,4</sup>, Ching-I Huang ([ching-i.huang@warwick.ac.uk](mailto:ching-i.huang@warwick.ac.uk))<sup>1,2</sup>, Maryam Aliee ([maryam.aliee@warwick.ac.uk](mailto:maryam.aliee@warwick.ac.uk))<sup>1,2</sup>, Fabrizio Tediosi ([fabrizio.tediosi@swissth.ch](mailto:fabrizio.tediosi@swissth.ch))<sup>3,4</sup>, Nakul Chitnis ([nakul.chitnis@unibas.ch](mailto:nakul.chitnis@unibas.ch))<sup>3,4</sup>, Matt J Keeling ([m.j.keeling@warwick.ac.uk](mailto:m.j.keeling@warwick.ac.uk))<sup>1,2,5</sup>

<sup>1</sup>Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK

<sup>2</sup>Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, Coventry, CV4 7AL, United Kingdom

<sup>3</sup>Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel, 4051, Switzerland

<sup>4</sup>University of Basel, Peterplatz 1, Basel, 4051, Switzerland

<sup>5</sup>School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK

We would like to thank Joshua Longbottom, Benjamin Amoah and Michelle Stanton for contributing to the priority questions in this article. We thank members of the Gates Foundation NTD team and WHO NTD team for providing valuable feedback on this article. Additionally, we are grateful to Andreia Vasconcelos for overlooking the development of this article. We thank Dr Erick Mwamba Miaka for his permission to include the DRC data map (Figure 1).

## References

1. **Global Health Observatory data repository [Internet].**  
[Reference Source](#)
2. Franco JR, Cecchi G, Priotto G, *et al.*: **Monitoring the elimination of human African trypanosomiasis: Update to 2016.** *PLoS Negl Trop Dis.* 2018; **12**(12): e0006890.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Franco JR, Cecchi G, Priotto G, *et al.*: **Monitoring the elimination of human African trypanosomiasis: Update to 2014.** *PLoS Negl Trop Dis.* 2017; **11**(5): e0005585.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Simarro PP, Cecchi G, Franco JR, *et al.*: **Monitoring the Progress towards the Elimination of Gambiense Human African Trypanosomiasis.** *PLoS Negl Trop Dis.* 2015; **9**(6): e0003785.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Mahamat MH, Peka M, Rayaisse JB, *et al.*: **Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad).** *PLoS Negl Trop Dis.* 2017; **11**(7): e0005792.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Rock KS, Torr SJ, Lumbala C, *et al.*: **Quantitative evaluation of the strategy to eliminate human African trypanosomiasis in the Democratic Republic of Congo.** *Parasit Vectors.* 2015; **8**(1): 532.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. WHO: **Control and surveillance of human African trypanosomiasis.** WHO Technical Report Series; 2013.  
[Reference Source](#)
8. Checchi F, Funk S, Chandramohan D, *et al.*: **The impact of passive case detection on the transmission dynamics of gambiense Human African Trypanosomiasis.** *PLoS Negl Trop Dis.* 2018; **12**(4): e0006276.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Castaño MS, Ndeffo-Mbah ML, Rock KS, *et al.*: **Assessing the impact of data aggregation in model predictions of HAT transmission and control activities.** *medRxiv.* 2019; 1–27.  
[Publisher Full Text](#)
10. Camara M, Ouattara E, Duvignaud A, *et al.*: **Impact of the Ebola outbreak on *Trypanosoma brucei gambiense* infection medical activities in coastal Guinea, 2014-2015: A retrospective analysis from the Guinean national Human African Trypanosomiasis control program.** *PLoS Negl Trop Dis.* 2017; **11**(11): e0006060.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Rock KS, Pandey A, Ndeffo-Mbah ML, *et al.*: **Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC.** *Epidemics.* 2017; **18**: 101–12.  
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Rock KS, Torr SJ, Lumbala C, *et al.*: **Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of Congo.** *PLoS Negl Trop Dis.* 2017; **11**(11): e0005162.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Sutherland CS, Stone CM, Steinmann P, *et al.*: **Seeing beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of *Trypanosoma brucei gambiense*.** *Lancet Glob Health.* 2017; **5**(1): e69–e79.  
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Courtin F, Camara M, Rayaisse JB, *et al.*: **Reducing Human-Tsetse Contact Significantly Enhances the Efficacy of Sleeping Sickness Active Screening Campaigns: A Promising Result in the Context of Elimination.** *PLoS Negl Trop Dis.* 2015; **9**(8): e0003727.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Tirados I, Esterhuizen J, Kovacic V, *et al.*: **Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy.** *PLoS Negl Trop Dis.* 2015; **9**(8): e0003822.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Checchi F, Funk S, Chandramohan D, *et al.*: **Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis.** *BMC Res Notes.* 2015; **8**(1): 292.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Sudarshi D, Lawrence S, Pickrell WO, *et al.*: **Human African trypanosomiasis presenting at least 29 years after infection--what can this teach us about the pathogenesis and control of this neglected tropical disease?** *PLoS Negl Trop Dis.* 2014; **8**(12): e33349.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Jamonneau V, Bucheton B, Kaboré J, *et al.*: **Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa.** *PLoS Negl Trop Dis.* 2010; **4**(12): e917.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Davis CN, Rock KS, Miaka EM, *et al.*: **Village-scale persistence and elimination of gambiense human African trypanosomiasis.** *medRxiv.* 2019; 19006502.  
[Publisher Full Text](#)
20. Informal Expert Group on Gambiense HAT Reservoirs, Büscher P, Bart JM, *et al.*: **Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination?** *Trends Parasitol.* 2018; **34**(3): 197–207.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Rock KS, Ndeffo-Mbah ML, Castaño S, *et al.*: **Assessing Strategies Against Gambiense Sleeping Sickness Through Mathematical Modeling.** *Clin Infect Dis.* 2018; **66**(suppl\_4): S286–S292.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Pandey A, Atkins KE, Bucheton B, *et al.*: **Evaluating long-term effectiveness of sleeping sickness control measures in Guinea.** *Parasit Vectors.* 2015; **8**(1): 550.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Kagbadouno MS, Camara O, Camara M, *et al.*: **Ebola outbreak brings to light an unforeseen impact of tsetse control on sleeping sickness transmission in Guinea.** *bioRxiv.* 2018; 1–9.  
[Publisher Full Text](#)
24. Sutherland CS, Tediosi F: **Is the elimination of 'sleeping sickness' affordable? Who will pay the price? Assessing the financial burden for the elimination of human African trypanosomiasis *Trypanosoma brucei gambiense* in sub-Saharan Africa.** *BMJ Glob Health.* 2019; **4**(2): e001173.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Funk S, Nishiura H, Heesterbeek H, *et al.*: **Identifying transmission cycles at the human-animal interface: the role of animal reservoirs in maintaining gambiense human african trypanosomiasis.** *PLoS Comput Biol.* 2013; **9**(1): e1002855.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Stone CM, Chitnis N: **Implications of Heterogeneous Biting Exposure and Animal Hosts on Trypanosomiasis *brucei gambiense* Transmission and Control.** *PLoS Comput Biol.* 2015; **11**(10): e1004514–22.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Capewell P, Atkins K, Weir W, *et al.*: **Resolving the apparent transmission paradox of African sleeping sickness.** *PLoS Biol.* 2019; **17**(1): e3000105.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

## Open Peer Review

Current Peer Review Status:  

---

### Version 1

Reviewer Report 07 November 2019

<https://doi.org/10.21956/gatesopenres.14204.r27989>

© 2019 Recker M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### Mario Recker

College of Engineering, Mathematics and Physical Sciences, University of Exeter, Penryn, UK

This open letter provides an overview of the use of mathematical modelling of gHAT and its uses in support of the WHO's target of global elimination of transmission by 2030. Coming from a modelling background but with little knowledge of gHAT I read this letter with much interest. However, what I feel is currently lacking is a bit more detail and structure regarding the models and their predictions themselves. That is, from the article it is clear that various models have been developed and that they have been applied to answer slightly different gHAT-related questions. What is not clear is what types of models have been used for what questions, where do models generally agree or disagree, what are crucial knowledge gaps highlighted by these exercises, and what is the direction that models should be heading to support local and global elimination efforts. I believe that much of this could be achieved simply by re-organisation/restructuring, making the sections more focused and less overlapping. For example, the problems of a potential animal reservoirs or asymptomatic infections come up more than once, the same with screening/diagnostics. Personally I would focus on just a few key obstacles, important aspects of gHAT epidemiology/elimination, or intervention measures, detailing the problem and then illustrating what modelling has found and/or how it can be used in the future. Also, the authors mention in the Abstract that accounting for uncertainties and stochastic effects is very important, which I fully agree with, especially as one approaches disease elimination scenarios. However, I was missing the discussion on this in the text; are none of the approaches developed so far stochastic/deal with uncertainty? Given its importance I would suggest that the authors could maybe dedicating a separate (sub-)section on this?

More specific comments:

- Background, second paragraph: maybe this is a bit negative but saying that 963 cases suggests that the first indication has been greatly surpassed the goal of getting it below 2000 is a bit of an exaggeration; to me this suggests things are on target
- Modelling insights from [...], first paragraph: it is not immediately obvious how staged gHAT case data can provide substantial information on the effectiveness of surveillance; more detail on this would be welcome

- Table 1: the question 'is the new target technical feasible [...]' is answered by 'yes'; but the next row goes into 'if not, what is required' - given that the first answer is yes, do we need this then? Or is the answer not really 'yes'
- EOT before zero reporting: what are 'algorithms' with 99.9% specificity?
- Zero reporting but not EOT: this seems to me like a two-part problem, the first is general under-reporting, and the other long periods of asymptomatic infections; would it be worth making this distinction?
- Zero reporting but not EOT, second paragraph: replace 'replaying' with 'simulating'
- Technical feasibility: explain why the strategy could achieve local EOT in some regions but not in others
- Ability to sustain achievement [...]: it seems like the issue about the potential animal reservoir is slightly controversial, i.e. what's the evidence for or against?
- Ability to sustain achievement [...], last paragraph: why is reintroduction less likely to cause persistent infections? Presumably control programs would stop after elimination has been achieved?
- Asymptomatic reservoirs: this is a clear example where it would be good to have more of an overall discussion on where models agree, where they differ and why.
- Table 2: do you need the second column, or would it be possible to have this table just listing/detailing (top priority) questions that can be addressed/answered with modelling? Personally I find that the 'how' is not that important, especially as no other model details and assumptions are being discussed here

Overall I think that this is an important piece of work highlighting the uses of mathematical models in public health, and a little more structured and focused approach would make it even better.

**Is the rationale for the Open Letter provided in sufficient detail?**

Yes

**Does the article adequately reference differing views and opinions?**

Yes

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**

Yes

**Is the Open Letter written in accessible language?**

Yes

**Where applicable, are recommendations and next steps explained clearly for others to follow?**

Yes

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Reviewer Report 29 October 2019

<https://doi.org/10.21956/gatesopenres.14204.r27987>

© 2019 Barrett M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Michael P. Barrett**

Wellcome Centre for Integrative Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

The open letter is a clear overview of modelling efforts tracing the road to elimination of gambiense HAT.

- Background: Paragraph 1, line 6: note parasites can cross the BBB before establishing themselves there to make stage 2 infection, so please change to reflect that.
- Line 11: After 37,385 - add the word "reported" before cases.
- Paragraph 2, line 4: 2,000 (add the comma). Line 9: Also add a comma to 1,419.
- Paragraph 3, line 10-11: place commas around "and likelihood of reaching".
- Table 1, point 5: I am not certain that "existing diagnostics are likely sufficient". If skin parasites are not sustaining serum antibody titres, and also if the standard antigens used in current tests are not present in a cohort of residual parasites it is likely the diagnostics will become ever less sensitive.
- On page 4: the reference to the trypanolysis test which purports 100% specificity is, I think, equally vulnerable to loss of sensitivity in cases where parasites not expressing antigens central to this test are in circulation.
- On page 5: Second paragraph points to the potential of animal reservoirs and asymptomatic individuals. However, the downward trend appears to have been following predictions quite nicely (where these refugia are not considered). Does the modelling so far, therefore, rule out a significant impact of the animal reservoir and asymptomatic patients, or does incidence have to get even lower before the problem will become manifest?
- Page 5. section Operational feasibility: It is stated that "Models are therefore making assumptions that screening and other controls follow recent trends." Can't the models themselves be used now to predict what happens in the event of different removal of control scenarios?
- Page 6, Last paragraph before the "Risks and unknowns....." section: This covers estimate of cost of control based on the Sutherland and Tediosi work. Clearly these estimates could have a large impact on policy decisions. Can the authors offer an opinion on how robust they consider those

findings (in the light of modelling predictions?)

- Page 6, column 2, section on "Movement", line 4: "formally" should be "formerly"
- References, reference 1: More information needed to access.
- Some references e.g. 4, 12, 14, 15, 20, 21, 26 are using capital first letters for individual words in the title, while others are not.

**Is the rationale for the Open Letter provided in sufficient detail?**

Yes

**Does the article adequately reference differing views and opinions?**

Yes

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**

Yes

**Is the Open Letter written in accessible language?**

Yes

**Where applicable, are recommendations and next steps explained clearly for others to follow?**

Yes

***Competing Interests:*** No competing interests were disclosed.

***Reviewer Expertise:*** African trypanosomiasis, drugs mode of action and resistance mechanisms

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**